Académique Documents
Professionnel Documents
Culture Documents
OUTLINE
Background
Aim
of study
Objectives
Methodology
Results
Discussion
Conclusions
Recommendations
BACKGROUND
Aim of study
To determine the prevalence of MDR-TB among HIV-TB coinfected patients using Hain Line-Probe Assay
(GenoTypeMTBDRplus)
METHODOLOGY
Study Site:
DOTS Clinic of NIMR, Lagos, Nigeria
Study type: Cross sectional
Study Period: January to November 2009
Study Population:
169 HIV Patients who were diagnosed to have TB
Inclusion Criteria:
Consenting patients
Ability to produce 3 sputum samples
Patients who were sputum smear- positive
Methodology.2
Exclusion criteria:
Patients who were HIV negative
Patients who were sputum smear-negative for TB
Ethical approval was obtained from NIMR Institutional Review Board
Laboratory diagnosis:
Sputum Specimens were examined for AFB using Ziel-Neelsen Method
(NTBLCP)
The sputum samples were graded by direct smear microscopy
( IUATLD)
Rapid Drug Resistance Testing for RIF mono -resistance, INH monoresistance and MDR-TB was performed according to the manufacturers
instructions (Hain Lifescience GenotypeMTBDR plusTM version1.0 product
insert)
Data analysis:
SPSS version 15.0 statistical software was used
Results were considered significant at P< 0.05
RESULTS
Percentage (%)
35
36.7
P=0.896(>0.05)
30
25
20
14.8
15
10
5
0
MTB
N-MTB
5.9
5.3
0.0
1.2
0.6
0.6
10 - 20
21 - 30
31 - 40
40 - 50
Age(years)
0.0
50+
55.6
P=0.471(>0.05)
Percentage (%)
50
42.0
40
MTB
N-MTB
30
20
10
1.8
0.6
0
MALE
Sex
FEMALE
MDR- TB
Y
N
RIF MONO-RES
Y
N
INH MONO-RES
Y
N
0 (0.0%)
4 (6.8%)
2(3.2%)
2(8.0%)
1(10.0%)
P = 0.925
1(11.1%) 8(88.9%)
7(11.9%) 52(88.1%)
11 (17.7%) 51(82.3%)
9(36.0%) 16(64.0%)
1(10.0%) 9(90.0%)
P = 0.355
0 (0.0%) 9(100)
2 (3.4%) 57(96.6%)
3(4.8%) 59(95.2%)
1(4.0%) 24(96.0%)
0(0.0%) 10(100%)
P = 0.978
9 (100%)
55 (93.2%)
60(96.8%)
23(92.0%)
9(90.0%)
7(7.4%) 87(92.6%)
2(2.8%) 69(97.2%)
P = 0.322
Category :
Old
New
DISCUSSION
CONCLUSIONS/ RECOMMENDATIONS
The
prevalence of MDR-TB among HIV and TB coinfected patients is documented. This strongly highlights
the need for the national strategies for surveillance and
effective clinical management of MDR-TB cases in
Nigeria
Although we recorded the prevalence of MDR-TB as
5.5% among HIV-TB co-infected Nigerians , 73.3% of
them were sensitive to both RIF and INH, the two most
import anti-TB first line drugs
GenoTypeMTBDRplus was able detect MDR-TB in
HIV-TB co-infected Nigerians which is ordinarily
difficult and should be used for rapid screening of MDRTB in Nigeria to achieve early detection and treatment
with appropriate drug regimen
THANK YOU